Hexvix Photodynamic Therapy in Patients With Bladder Cancer

This study has been completed.
Karl Storz
Information provided by:
ClinicalTrials.gov Identifier:
First received: February 18, 2011
Last updated: February 24, 2011
Last verified: February 2011
The purpose of the study is to investigate the safety and feasibility of Hexaminolevulinate based photodynamic therapy in patients with intermediate or high-risk transitional cell carcinoma of the bladder.

Condition Intervention Phase
Intermediate or High-risk Bladder Cancer
Other: Hexvix PDT with Karl Storz T-Light
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Feasibility Study of Hexvix Photodynamic Therapy in Patients With Intermediate or High-risk Bladder Cancer

Resource links provided by NLM:

Further study details as provided by Photocure:

Primary Outcome Measures:
  • Number of patients with adverse events [ Designated as safety issue: Yes ]

    To assess the safety of photodynamic therapy (PDT) using Hexvix and the Karl Storz T-light PDT System in patients with recurrent bladder cancer.

    (assessment of adverse events, blood biochemistry, vital signs, urodynamics)

Secondary Outcome Measures:
  • The number of tumour-free patients after 6 months [ Designated as safety issue: No ]
    To assess the efficacy of Hexvix PDT in patients with intermediate and high-risk bladder cancer

Enrollment: 17
Study Start Date: March 2005
Study Completion Date: August 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Hexvix PDT Other: Hexvix PDT with Karl Storz T-Light

Detailed Description:
Non-muscle invasive bladder cancer is currently treated by transurethral resection (TURB) and/or fulguration. However, recurrence and progression rates following endoscopic treatment of visible lesions are significant. To prevent recurrent and progressive disease, adjuvant intravesical chemotherapy and immunotherapy are applied. There is also increasing interest in new therapeutic strategies such as photodynamic therapy.

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female aged 18 years or above who have given written informed consent.
  • Patients with intermediate or high-risk superficial bladder cancer, defined as low-grade early recurrence within 6 months after local chemotherapy or BCG, primary or recurrent high-grade disease (TaG3, TaG3 with CIS or CIS alone) or patients with primary T1G3 who are tumour free at second resection.

Exclusion Criteria:

  • Patients with muscle invasive tumour
  • Patients with bladder shrinkage
  • Patients who have received prior PDT for bladder cancer
  • History of T1G3 disease or other indications for cystectomy
  • Patient with porphyria
  • Gross haematuria. (Note: Gross haematuria is defined as a heavy bladder bleed resulting in marked amounts of blood in the urine, which may interfere with PDT)
  • Patients who have received BCG or chemotherapy within three months prior to Hexvix instillation, except for a single dose of chemotherapy for prevention of seeding after resection
  • Known allergy to hexaminolevulinate or a similar compound
  • Participation in other clinical studies either concurrently or within the last 30 days
  • Women of child-bearing potential.
  • Conditions associated with a risk of poor protocol compliance
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01303991

Sponsors and Collaborators
Karl Storz
Principal Investigator: Dirk Zaak, MD Urology Department, Medizinische Fakultät der LMU Muenchen
  More Information

Responsible Party: Photocure ASA
ClinicalTrials.gov Identifier: NCT01303991     History of Changes
Other Study ID Numbers: PC B251/03 
Study First Received: February 18, 2011
Last Updated: February 24, 2011
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Additional relevant MeSH terms:
Urinary Bladder Neoplasms
Neoplasms by Site
Urinary Bladder Diseases
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms

ClinicalTrials.gov processed this record on May 26, 2016